[
  {
    "ts": null,
    "headline": "Jim Cramer on Eli Lilly and Company (LLY): ‘I See Things Going Back To Normal For Eli Lilly’",
    "summary": "We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently reflected on how investors often overlook […]",
    "url": "https://finnhub.io/api/news?id=fe15d8c9a1f95ef355f7f10db2ef445f499fc7f5f2ddda3ec7b0edd573d066cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734643331,
      "headline": "Jim Cramer on Eli Lilly and Company (LLY): ‘I See Things Going Back To Normal For Eli Lilly’",
      "id": 132071763,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently reflected on how investors often overlook […]",
      "url": "https://finnhub.io/api/news?id=fe15d8c9a1f95ef355f7f10db2ef445f499fc7f5f2ddda3ec7b0edd573d066cc"
    }
  },
  {
    "ts": null,
    "headline": "Novo Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal",
    "summary": "Henrik Wulff, the man in charge of product supply at  Novo Nordisk  just spent $11 billion to try to fill an ocean.  Novo has handed Wulff one of the most complex jobs in all of pharmaceuticals.  Novo and its competitor  Eli Lilly  have gone to greater and greater lengths to speed their GLP-1 output, as they battle each other and the increasingly aggressive telehealth industry, which is selling large quantities of legal GLP-1 knockoffs.",
    "url": "https://finnhub.io/api/news?id=374a0f9e8a285ac4fc8b49dd0140eac8081102a055ad70cf935c273c31a1fa4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734643260,
      "headline": "Novo Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal",
      "id": 132065737,
      "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Henrik Wulff, the man in charge of product supply at  Novo Nordisk  just spent $11 billion to try to fill an ocean.  Novo has handed Wulff one of the most complex jobs in all of pharmaceuticals.  Novo and its competitor  Eli Lilly  have gone to greater and greater lengths to speed their GLP-1 output, as they battle each other and the increasingly aggressive telehealth industry, which is selling large quantities of legal GLP-1 knockoffs.",
      "url": "https://finnhub.io/api/news?id=374a0f9e8a285ac4fc8b49dd0140eac8081102a055ad70cf935c273c31a1fa4b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lily GLP-1 shortage ends, FDA says: Hims & Hers stock falls",
    "summary": "Hims & Hers Health (HIMS) shares tumble after the US Food and Drug Administration (FDA) announced that the shortage in Eli Lilly's (LLY) weight loss drug, Zepbound, has been resolved. The stock falls in anticipation of lower demand as the supply of GLP-1 weight-loss drugs improves. Julie Hyman and Josh Lipton examine the stock move and what investors need to know about the evolving GLP-1 market. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.",
    "url": "https://finnhub.io/api/news?id=359954fd3484bb1e77ea0c6a15497f15c6dce5fc6b393de9b1397c1f45c5fe0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734642200,
      "headline": "Eli Lily GLP-1 shortage ends, FDA says: Hims & Hers stock falls",
      "id": 132061871,
      "image": "https://s.yimg.com/ny/api/res/1.2/RTU31JGFE.631e60TCeuGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/2c0a4570-be4b-11ef-bdfe-872216a21613",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers Health (HIMS) shares tumble after the US Food and Drug Administration (FDA) announced that the shortage in Eli Lilly's (LLY) weight loss drug, Zepbound, has been resolved. The stock falls in anticipation of lower demand as the supply of GLP-1 weight-loss drugs improves. Julie Hyman and Josh Lipton examine the stock move and what investors need to know about the evolving GLP-1 market. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.",
      "url": "https://finnhub.io/api/news?id=359954fd3484bb1e77ea0c6a15497f15c6dce5fc6b393de9b1397c1f45c5fe0e"
    }
  },
  {
    "ts": null,
    "headline": "FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next",
    "summary": "The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end.",
    "url": "https://finnhub.io/api/news?id=6980ca3a9cb645f8c2fd0952096a961b6393aabc89c27e572e0161c42dbecb9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734641827,
      "headline": "FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next",
      "id": 132058014,
      "image": "https://s.yimg.com/ny/api/res/1.2/OXbHdXuCPsV4JzIEOo1Jzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-01/4b4e6630-c4e8-11ee-b97f-1f73ddd2dfaf",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end.",
      "url": "https://finnhub.io/api/news?id=6980ca3a9cb645f8c2fd0952096a961b6393aabc89c27e572e0161c42dbecb9f"
    }
  },
  {
    "ts": null,
    "headline": "In weight loss battle, Novo and Lilly face growing offensive from licenced copies",
    "summary": "As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a...",
    "url": "https://finnhub.io/api/news?id=ac88d93bc7156cf9bb384701347400f6e694aa216eb6b9fd40d02cee9c94939f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734638586,
      "headline": "In weight loss battle, Novo and Lilly face growing offensive from licenced copies",
      "id": 132060656,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a...",
      "url": "https://finnhub.io/api/news?id=ac88d93bc7156cf9bb384701347400f6e694aa216eb6b9fd40d02cee9c94939f"
    }
  },
  {
    "ts": null,
    "headline": "FDA says knockoff versions of Lilly obesity drug must come off the market",
    "summary": "Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase out their versions next year under a federal decision issued Thursday.  The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become wildly popular with Americans trying to lose weight.  The decision is a win for Lilly — which had been pressing the FDA to take the step for months — and is expected to impact how patients access the drugs, including how much they pay.",
    "url": "https://finnhub.io/api/news?id=02041c8fa031f07ffb094b7de6e581aef3ff7d2504d72a5d916c902e97a4ac1c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734638557,
      "headline": "FDA says knockoff versions of Lilly obesity drug must come off the market",
      "id": 132057130,
      "image": "https://s.yimg.com/ny/api/res/1.2/iMbUgqVw5ut4OTMs6tFvlw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/ap_finance_articles_694/3157f47f3758d58fc202484c43a8a1ab",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase out their versions next year under a federal decision issued Thursday.  The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become wildly popular with Americans trying to lose weight.  The decision is a win for Lilly — which had been pressing the FDA to take the step for months — and is expected to impact how patients access the drugs, including how much they pay.",
      "url": "https://finnhub.io/api/news?id=02041c8fa031f07ffb094b7de6e581aef3ff7d2504d72a5d916c902e97a4ac1c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=137a35e91f77d6e121784148910f88c9de134ed0d20f7056d2994266def2aded",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734625980,
      "headline": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
      "id": 132064396,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=137a35e91f77d6e121784148910f88c9de134ed0d20f7056d2994266def2aded"
    }
  },
  {
    "ts": null,
    "headline": "IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List",
    "summary": "Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage.",
    "url": "https://finnhub.io/api/news?id=e22856d596e669c09518263fa070538217ee44cbbe4f35528472e400e2500eee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734625365,
      "headline": "IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List",
      "id": 132054702,
      "image": "https://media.zenfs.com/en/ibd.com/3479e7a00dca742e5b00b347f39012d3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage.",
      "url": "https://finnhub.io/api/news?id=e22856d596e669c09518263fa070538217ee44cbbe4f35528472e400e2500eee"
    }
  },
  {
    "ts": null,
    "headline": "FDA Says Shortage of Eli Lilly’s Zepbound Is Over, but Gives Compounders a Grace Period",
    "summary": "FDA Says Shortage of Eli Lilly’s Zepbound Is Over, but Gives Compounders a Grace Period",
    "url": "https://finnhub.io/api/news?id=9b34006fc471c10ba02cb88e1e0b90bb71649f7ed48481b7072c4c7126d80e24",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734617760,
      "headline": "FDA Says Shortage of Eli Lilly’s Zepbound Is Over, but Gives Compounders a Grace Period",
      "id": 132064399,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "FDA Says Shortage of Eli Lilly’s Zepbound Is Over, but Gives Compounders a Grace Period",
      "url": "https://finnhub.io/api/news?id=9b34006fc471c10ba02cb88e1e0b90bb71649f7ed48481b7072c4c7126d80e24"
    }
  },
  {
    "ts": null,
    "headline": "Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug",
    "summary": "Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.",
    "url": "https://finnhub.io/api/news?id=083f981a62a40c54ded151168c5d691c3d7cbb33254b17ed0f73c178b267b55b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734614640,
      "headline": "Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug",
      "id": 132051883,
      "image": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.",
      "url": "https://finnhub.io/api/news?id=083f981a62a40c54ded151168c5d691c3d7cbb33254b17ed0f73c178b267b55b"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Competition Fears Are Exaggerated",
    "summary": "Viking Therapeutics shows promise with weight loss drug VK2735 and potential in NASH treatment, making it a potential takeover target. Read more on VKTX here.",
    "url": "https://finnhub.io/api/news?id=f68f0ab502abbaa2855584a34573a73d3d30cef19848c50d38bb6cd463a08728",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734609342,
      "headline": "Viking Therapeutics: Competition Fears Are Exaggerated",
      "id": 132053590,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1719209231/image_1719209231.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics shows promise with weight loss drug VK2735 and potential in NASH treatment, making it a potential takeover target. Read more on VKTX here.",
      "url": "https://finnhub.io/api/news?id=f68f0ab502abbaa2855584a34573a73d3d30cef19848c50d38bb6cd463a08728"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?",
    "summary": "It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry.  What's more, since the new payouts will represent the two companies' first dividends of 2025, there's still time for investors to take advantage of them.  You would be hard-pressed to find a pharmaceutical sector dividend that's as reliable as that of Bristol Myers Squibb's. The company has been doling out a shareholder distribution for 93 years.",
    "url": "https://finnhub.io/api/news?id=c1c350b30832646f1320d7bcbcd48748370f7d468a13306ab4e8d2b00fb82995",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734603960,
      "headline": "These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?",
      "id": 132054704,
      "image": "https://g.foolcdn.com/editorial/images/801021/two-people-in-white-lab-coats-looking-at-a-computer-display.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry.  What's more, since the new payouts will represent the two companies' first dividends of 2025, there's still time for investors to take advantage of them.  You would be hard-pressed to find a pharmaceutical sector dividend that's as reliable as that of Bristol Myers Squibb's. The company has been doling out a shareholder distribution for 93 years.",
      "url": "https://finnhub.io/api/news?id=c1c350b30832646f1320d7bcbcd48748370f7d468a13306ab4e8d2b00fb82995"
    }
  },
  {
    "ts": null,
    "headline": "This Is Huge News for Eli Lilly Investors",
    "summary": "Eli Lilly just gave investors several reasons to cheer.",
    "url": "https://finnhub.io/api/news?id=2016a694cad1723521850a0969ff32039901bc6f3328f30a6d94b71c8bc6224f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734601440,
      "headline": "This Is Huge News for Eli Lilly Investors",
      "id": 132051887,
      "image": "https://g.foolcdn.com/editorial/images/801177/gettyimages-2024514092.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly just gave investors several reasons to cheer.",
      "url": "https://finnhub.io/api/news?id=2016a694cad1723521850a0969ff32039901bc6f3328f30a6d94b71c8bc6224f"
    }
  },
  {
    "ts": null,
    "headline": "Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook",
    "summary": "Eli Lilly's diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide, support a \"buy\" rating for long-term investors. Read more here.",
    "url": "https://finnhub.io/api/news?id=5bd860a24ccf9348a31d5131070fbe5d2a1a9133fe03c86efb2730eb7a42ceca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734591600,
      "headline": "Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook",
      "id": 132049613,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155432072/image_155432072.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide, support a \"buy\" rating for long-term investors. Read more here.",
      "url": "https://finnhub.io/api/news?id=5bd860a24ccf9348a31d5131070fbe5d2a1a9133fe03c86efb2730eb7a42ceca"
    }
  },
  {
    "ts": null,
    "headline": "The Gabelli Enterprise Mergers & Acquisitions Fund Q3 2024 Commentary",
    "summary": "The Gabelli Enterprise Mergers & Acquisitions Fund (class I) returned 7.72% for the third quarter of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=06aebb540d007942833268a4c2ff19399336104690f21ede794ba314f102351a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734590400,
      "headline": "The Gabelli Enterprise Mergers & Acquisitions Fund Q3 2024 Commentary",
      "id": 132049430,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389510306/image_1389510306.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Gabelli Enterprise Mergers & Acquisitions Fund (class I) returned 7.72% for the third quarter of 2024. Click here to read the full commentary. \n",
      "url": "https://finnhub.io/api/news?id=06aebb540d007942833268a4c2ff19399336104690f21ede794ba314f102351a"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Had a Dismal Year. Therein Lies Opportunity, Says This Analyst",
    "summary": "Goldman Sachs’ Asad Haider likes the prospects for medical technology companies, mid-cap biotechs, drug distributors.",
    "url": "https://finnhub.io/api/news?id=af7ad4cd81f137f7aefc040657af620f90c3bb721b86d2065884f3dbfc32e07e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734584700,
      "headline": "Healthcare Stocks Had a Dismal Year. Therein Lies Opportunity, Says This Analyst",
      "id": 132045399,
      "image": "https://s.yimg.com/ny/api/res/1.2/vHcIcu6RzA9bhOB_lyhuyQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/2925f980cc4c554ced691f1c0bbe23ba",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Goldman Sachs’ Asad Haider likes the prospects for medical technology companies, mid-cap biotechs, drug distributors.",
      "url": "https://finnhub.io/api/news?id=af7ad4cd81f137f7aefc040657af620f90c3bb721b86d2065884f3dbfc32e07e"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Had a Dismal Year. Therein Lies Opportunity, Says This Analyst.",
    "summary": "Healthcare Stocks Had a Dismal Year. Therein Lies Opportunity, Says This Analyst.",
    "url": "https://finnhub.io/api/news?id=aa7ea5476f27dfcde053969034f4c235fdcbedf92bdf515eef27d73e6559dadd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734566700,
      "headline": "Healthcare Stocks Had a Dismal Year. Therein Lies Opportunity, Says This Analyst.",
      "id": 132064401,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Healthcare Stocks Had a Dismal Year. Therein Lies Opportunity, Says This Analyst.",
      "url": "https://finnhub.io/api/news?id=aa7ea5476f27dfcde053969034f4c235fdcbedf92bdf515eef27d73e6559dadd"
    }
  }
]